Orexigen Therapeutics, Inc. OREX saw a big move in the last trading session, as the company's shares fell by nearly 15% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent uptrend for OREX, as the stock is up nearly 7% in the past one-month time frame.
The biopharmaceutical company has not seen any estimate revision over the past month, and the current year earnings consensus hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, especially on earnings estimates following the recent slump.
OREX currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is positive.
Investors interested in the Drugs industry may consider better-ranked stocks like ANI Pharmaceuticals, Inc. ANIP, Gilead Sciences Inc. GILD and Osiris Therapeutics, Inc. OSIR, each of which holds a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OREXIGEN THERAP OREX: Free Stock Analysis Report
ANI PHARMACEUT ANIP: Free Stock Analysis Report
GILEAD SCIENCES GILD: Free Stock Analysis Report
OSIRIS THERAPTC OSIR: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: MoversTrading Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
